Concord Biotech Limited Q2 & H1 FY26 Concall Decoded: Timing issues nuked Q2, EBITDA secretly at 41%, and management betting big on injectables & CDMO

1. Opening Hook

Concord Biotech’s Q2 numbers looked like someone hit the pause button mid-quarter. EU approvals got stuck, Middle East geopolitics entered the chat, and US customers suddenly decided to “wait and watch.” Result? A headline revenue dip that scared the impatient.

But scratch the surface and the story flips. Shipments weren’t cancelled—just delayed. Margins didn’t collapse—they were masked by startup costs. And the biggest capex bet, injectables, hasn’t even started flexing yet.

Management sounded irritated but calm. They’ve seen this movie before. The punchline, according to them, lands in H2.

So was Q2 a genuine slowdown—or just an accounting awkward pause before the rebound?

Read on, because behind the weak topline is a company quietly building regulatory firepower and long-cycle growth engines.

2. At a Glance

Revenue ₹247 cr: YoY down 20%, but QoQ up 21%—confusing at first glance.
H1 Revenue ₹451 cr: Timing issues stole ~₹45 cr, management says “not lost.”
EBITDA margin 36%: Looks weak—until injectables costs are stripped out.
EBITDA (adj.) 41%: The real number management wants you to look at.
PAT ₹107 cr (H1): Margins held despite revenue pain.
Injectables drag: Startup costs today, profit promises tomorrow.

3. Management’s Key Commentary

“This is a timing difference, not loss of business.”
(Translation: Calm down, shipments were stuck—not customers 😏)

“Written Confirmation from CDSCO delayed EU shipments.”
(Translation: Paperwork beat production this quarter.)

“Excluding injectables, EBITDA margin stood at 41%.”
(Translation: Core business is still a margin monster.)

“The injectable facility will contribute positively as utilization improves.”
(Translation: Capex pain now, bragging rights later.)

“US procurement shifted due to tariff uncertainty.”
(Translation: Trump headlines messed with purchase orders.)

“We remain confident of a stronger H2.”
(Translation: Q2 was ugly, Q3 better behave 🙂)

4. Numbers Decoded

Source table

Metric	Q2 FY26	What It Really Means
Revenue	₹247 cr	Deferred, not destroyed
EBITDA	₹88 cr	QoQ up 44%, optics poor
EBITDA Margin	36%	Suppressed by injectables
Adj. EBITDA Margin	41%	True operating strength
PAT Margin	24%	Still very healthy
Deferred Revenue	~₹45 cr	Mostly shifts to Q3

One-liner: Numbers look weak, economics don’t.

5. Analyst Questions

EU delay impact? ~₹20–25 cr shifted to Q3 after CDSCO approval came on Nov 4.
Middle East tender? ~₹20 cr deferred; reopening depends on geopolitics.
US slowdown structural? No—tariff clarity restored

To Read Full 16 Point